Michiel Van der Heijdan received his medical degree from the Erasmus University in Rotterdam in 2002 and his PHD degree in 2005 at the University of Amsterdam, on work done in Scott Kern’s laboratory at St John Hopkins University in Baltimore (pancreatic cancer genetics). He then went on to do his internal medicine residency at the Academic Medical Centre in Amsterdam (2005-2009) and his medical oncology fellowship at the Netherlands Cancer Institute in Amsterdam (2011-2013). Dr Heijdan’s medical training was briefly interrupted by a laboratory research fellowship with Rene Bernards at the Netherlands Cancer Institute. Since 2013, Dr Heijdan has been working as a medical oncologist research group leader at the Netherlands Cancer Institute. His work focusses on the improvement of clinical treatment of bladder cancer, with a special interest in immunotherapy in early disease settings and translational research into the reasons for (non) response to therapy.
Disclosures
Michiel Van der Heijdan discloses the following relationships and financial interests. He has been an invited speaker, has participated in compensated activities, has received financial support/sponsorship from Companies including; Bristol Myers Squibb, Roche, AstraZeneca Janssen and Seattle Genetics.
All relevant financial relationships have been mitigated.